Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of an H+, K+ -ATPase inhibitor in the treatment of asthma

Inactive Publication Date: 2006-02-02
LINDBERG PER +3
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a new treatment for nasal polyps using proton pump inhibitors (PPIs). These PPIs are already used to treat gastric acid-related diseases and are known to inhibit the final step of acid secretion in the stomach. The invention is based on the discovery that PPIs can also reduce the size of nasal polyps and maintain them in a reduced state. The use of PPIs for the treatment of nasal polyps has been shown to be effective in reducing the size of polyps and preventing them from coming back after treatment. The invention provides a new and effective treatment for nasal polyps that has been difficult to treat using existing methods."

Problems solved by technology

Their paleness is generally due to poor blood supply.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of an H+, K+ -ATPase inhibitor in the treatment of asthma
  • Use of an H+, K+ -ATPase inhibitor in the treatment of asthma
  • Use of an H+, K+ -ATPase inhibitor in the treatment of asthma

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0028] A 53 year old woman who had had Widal's Syndrome for several years but who had refused surgical treatment of her polyps suffered mild upper abdominal pain and no improvement in the polyps after treatment by topical and systemic corticosteroids. However within two weeks of being prescribed 20 mg of omeprazole per day in addition to 100 μg of budesonide (Aqua preparation) per nostril / b.i.d. and 6 mg of deflazacort per day, she experienced a progressive improvement in her nasal respiratory problem. Eventually she recovered completely from the polyps.

examples 2 to 10

[0029] Nine patients, each with the conditions shown in the following Table 1, were treated during a two week period. The treatment consisted of 20 mg of omeprazole, 100 μg of intranasal budesonide and 3 to 15 mg of oral deflazacort (deflazacort was used in such a small quantity to ensure the patients' compliance). The results are also shown in Table 1.

TABLE 1Example No.ConditionResult2Widal's SyndromeTemporary benefit3Widal's SyndromePositive effect4Widal's SyndromePositive effect5Nasal PolyposisLong term benefit6Nasal PolyposisNo benefit7Nasal PolyposisPositive effect8Nasal PolyposisPositive effect9Nasal Polyposis and aspirinPositive effectintolerance 10 --Nasal Polyposis and asthmaNo benefit

[0030] Where a positive effect is indicated, this means that the patient experienced a decrease in rhinorrhoea, a marked improvement in nasal respiratory ventilation and a reduction in the size of the polyps. The patient who experienced a temporary benefit by the treatment suffered a recurre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
gastric acid secretionaaaaaaaaaa
alkalineaaaaaaaaaa
Login to View More

Abstract

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.

Description

FIELD OF THE INVENTION [0001] The present invention provides a new treatment for polyposis using proton pump inhibitors (PPIs), i.e. H+, K+-ATPase inhibitors. BACKGROUND OF THE INVENTION [0002] Polyposis can generally arise in the nose and the gastrointestinal tract. In the nose, polyps are pale bags of tissue that arise in the nasal cavity. Their paleness is generally due to poor blood supply. It is not known what causes the polyps to be formed but their presence is often associated with certain medical conditions, for example asthma and aspirin intolerance. Within the general population the incidence of nasal polyps is low at around only 1% but 13% of asthma sufferers and 36% of aspirin intolerant asthmatics suffer from nasal polyposis. The triple condition of nasal polyposis, aspirin intolerance and asthma is known as Widal's Syndrome. [0003] Nasal polyposis is generally treated in two stages. Initially a reduction in size of the polyps is achieved either by surgery or by the app...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4439A61K31/4184A61K31/00A61K31/435A61K31/444A61K31/57
CPCA61K31/00A61K31/4184A61K31/435A61K31/4439A61K31/57A61K31/444A61K2300/00A61K31/573A61K9/0014A61K45/06A61K31/437A61K31/56A61K31/58
Inventor LINDBERG, PERPINAS-MASSO, JOANSERRA-CARRERAS, JORDITROFAST, JAN
Owner LINDBERG PER